Business
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes
About this update from Milestone Pharmaceuticals Inc.
[{"type":"text","content":"- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p","length":237,"tagName":"div"}]